Answers are grounded in this paper and cite their sources.
Background & Aims:There is inadequate information available about the genomics and proteomics characterization of SARS-CoV-2 isolates reported from India and other part of the globe.This characterization is important for the in-silico drug designing, as there are no approved medications available to treat SARS-CoV-2 infection.The present study based on the characterization of SARS-CoV-2 (MZ558159) isolate reported from India using homology modeling, validation, and in silico drug designing methods. Materials & Methods:Genome sequence of SARS-CoV-2 (MZ558159) was retrieved from NCBI, and four protein sequences e.g., QXN18496, QXN18498, QXN18504, and QXN18497 were selected for the homology modeling, validation, and in silico drug designing.SWISS-MODEL and UCLA-DOE server were used for homology modeling.Validation for structure model performed using PROCHECK and molecular docking using MCULE-1-Click server.Results: The surface glycoprotein (QXN18496) model corresponding to probability conformation with 93.6%, envelope protein (QXN18498) with 88.9%, nucleocapsid phosphoprotein (QXN18504) with 93.6%, and ORF3a protein (QXN18497) with 91.8% residues in core section of φ-ψ plot that specifies accuracy of prediction models.The corresponding ProSA Z-score score -12.67, -0.01, -4.4, and -2.87 indicates the good quality of the models.Molecular dynamic simulation and docking studies revealed that inhibitor binds effectively at the SARS-CoV-2 (MZ558159) proteins.Predicted inhibitor 2-acetamido-2-deoxy-beta-D-glucopyranose exhibited effective binding affinity against surface glycoprotein (QXN18496). Conclusion:The results of this study established inhibitor 2-Acetamido-2-deoxy-beta-D-glucopyranose as valuable lead molecule with great potential for surface glycoprotein (QXN18496).
No takes yet. Share an insight, caveat, or question.
Rajneesh Prajapat (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: